FDA Approval Decisions Report
March, 2010
| Date: | Mar 01, 2010 |
|---|---|
| Format: | ZIP |
| Price: | $125.00 |
Abstract
The Revere FDA Approval Decision Report report provides one of the most comprehensive and accurate event calendars for PDUFA dates (Prescription Drug User Fee Act) -- expected FDA approval dates for NDA/BLA filed drugs in the next 3 months and reviews all FDA approval decisions in the current month.
Furthermore, the report also analyzes each drug candidate's likelihood of approval and competitive landscape using 3 criteria derived from Revere's patented classification system:
- Utilization of a mechanism of action previously approved by the FDA.
- Facing two or fewer alternative drugs with the same mechanism of action for the same indication.
- Would be the first or second FDA approved drug for the company.
Included Bonus New BioMedicine Biotech Research Reports
- Exelixis, Inc. (EXEL) - Special Event Report - Phase 3 announcement of XL184
- Sucampo Pharmaceuticals, Inc. (SCMP) - Special Event Report - Phase 3 announcement of Amitiza
Each New BioMedicine Biotech Research Report provides in-depth analysis relating to an upcoming event for a select pipeline drug. The report forecasts the expected event outcome (positive/negative), and discusses the relevant company, the drug candidate, market opportunity, clinical trials results, and competitive landscape.
The Biotech Research Report is unique in its focus on events likely to drive large price movements within narrow timeframes, and because it forecasts event outcomes based on rigorous analysis of clinical results and regulatory factors.
Companies Mentioned in the Report
- Abbott Laboratories (ABT) - Overview - Reports
- AP Pharma Inc (APPA) - Overview - Reports
- Alkermes, Inc. (?978543) - Overview - Reports
- Amylin Pharmaceuticals, Inc. (AMLN) - Overview - Reports
- Cell Therapeutics, Inc. (CTIC) - Overview - Reports
- Cephalon Inc (?204110) - Overview - Reports
- Eli Lilly & Co. (LLY) - Overview - Reports
- General Electric Co (GE) - Overview - Reports
- Gilead Sciences, Inc. (GILD) - Overview - Reports
- GlaxoSmithKline plc (ADR) (GSK) - Overview - Reports
- Biogen Idec Inc. (BIIB) - Overview - Reports
- Merck & Co., Inc. (MRK) - Overview - Reports
- OSI Pharmaceuticals, Inc. (CH716923BCN8001:MSTAR:US) - Overview - Reports
- Pfizer Inc. (PFE) - Overview - Reports
- Par Pharmaceutical Companies, Inc. (PRX) - Overview - Reports
- Shire Plc. (ADR) (SHPGY) - Overview - Reports
- Watson Pharmaceuticals, Inc. (WPI) - Overview - Reports
- AstraZeneca plc (ADR) (AZN) - Overview - Reports
- Bayer AG (BAYRY) - Overview - Reports
- Dendreon Corporation (DNDN) - Overview - Reports
- Roche Holding AG (RHHBY) - Overview - Reports
- Actelion Ltd. (ALIOY) - Overview - Reports
- InterMune, Inc. (ITMN) - Overview - Reports
- Salix Pharmaceuticals, Ltd. (SLXP) - Overview - Reports
- POZEN Inc. (POZN) - Overview - Reports
- Sanofi (SNY) - Overview - Reports
- XenoPort, Inc. (XNPT) - Overview - Reports
- MannKind Corporation (MNKD) - Overview - Reports
- Zalicus, Inc. (ZLCS) - Overview - Reports
- ChemGenex Pharmaceuticals Limited (ADR) (?348233) - Overview - Reports
- Somaxon Pharmaceuticals, Inc. (SOMX) - Overview - Reports
- Cadence Pharmaceuticals, Inc. (CADX) - Overview - Reports
- Dainippon Sumitomo Pharma Co Ltd (DNPUY) - Overview - Reports
- Covidien plc (COV) - Overview - Reports
More Information:
Learn more about FDA Approval Decisions Report.